ERK pathway activation is required for amyloid-β1-40- induced neurotoxicity of THP-1 human monocytes towards SK-N-SH neuroblastoma

Brain Research

Volumn 1378, Issue , 2011, Pages 9-17

  Yin, Lin Lin ^a   Li, Wei ^b   Chu, Yan Qi ^a   Li, Lin ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Amyloid 1 40; Inflammation; PTK MEK ERK pathway; SK N SH neuroblastoma cell; THP 1 monocyte

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMYLOID BETA PROTEIN[1-40]; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYCLOOXYGENASE 2; DIMETHYL SULFOXIDE; GENISTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 8; MERCAPTOETHANOL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRUVATE SODIUM; TUMOR NECROSIS FACTOR ALPHA; WORTMANNIN;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL FREE SYSTEM; CELL LYSATE; CELL PROTECTION; CELL STRAIN; CELL STRAIN SK N SH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MONOCYTE; MOUSE; NEUROBLASTOMA CELL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOIMMUNOASSAY; RADIOIMMUNOPRECIPITATION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; BLOTTING, WESTERN; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; ENZYME ACTIVATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INFLAMMATION; MAP KINASE SIGNALING SYSTEM; MICROSCOPY, ELECTRON, TRANSMISSION; MONOCYTES; NEUROBLASTOMA; NEURONS; PEPTIDE FRAGMENTS;

EID: 79951956132     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2011.01.013     Document Type: Article

References (35)

1. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G.M., Cooper, N.R., Eikelenboom, P., Emmerling, M., Fiebich, B.L., et al., 2000. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421. (Pubitemid 30349107)
2. Asanuma, M., Miyazaki, I., Ogawa, N., 2004. Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative disease. Curr. Pharm. Des. 10, 695-700.
3. Basu, A., Krady, J.K., Enterline, J.R., Levision, S.W., 2002. Transforming growth factor beta1 prevents IL-1beta-induced microglial activation, whereas TNF alpha- and IL-6- stimulated activation are not antagonized. Glia 40, 109-120. (Pubitemid 35181348)
4. Broe, G.A., Grayson, D.A., Creasey, H.M., Waite, L.M., Casey, B.J., Bennett, H.P., Brooks, W.S., Halliday, G.M., 2000. Anti-inflammatory drugs protect against Alzheimer's disease at low doses. Arch. Neurol. 57, 1586-1591.
5. Casal, C., Serratosa, J., Tusell, J.M., 2002. Relationship between beta-AP peptide aggregation and microglial activation. Brain Res. 928, 76-84. (Pubitemid 34159054)
6. Castano, E.M., Frangione, B., 1991. Alzheimer's disease from the perspective of the systemic and localized forms of amyloidosis. Brain Pathol. 1, 263-271.
7. Combs, C., Karlo, J.C., Kao, S.C., Landreth, G.E., 2001. β-Amyloid stimulation of microglia and monocytes results in TNF-α-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. 21, 1179-1188. (Pubitemid 32128763)
8. De Felice, F.G., Vieira, M.N., Saraiva, L.M., Figueroa-Villar, J.D., Garcia-Abreu, J., Liu, R., Chang, L., Klein, W.L., Ferreira, S.T., 2004. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. FASEB J. 18, 1366-1372. (Pubitemid 39150351)
9. Ezoulin, M.J., Ombetta, J.E., Dutertre-Catella, H., Warnet, J.M., Massicot, F., 2008. Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells. Neurotoxicology 29, 270-277.
10. Giri, R.K., Selvaraj, S.K., Kalra, V.K., 2003. Amyloid peptide-induced cytokine and chemokine expression in THP-1 monocytes is blocked by small inhibitory RNA duplexes for early growth response-1 messenger RNA. J. Immunol. 170, 5281-5294. (Pubitemid 36554763)
11. Grace, E.A., Rabiner, C.A., Busciglio, J., 2002. Characterization of neuronal dystrophy induced by fibrillar amyloid beta: implications for Alzheimer's disease. Neuroscience 114, 265-273. (Pubitemid 35247506)
12. Hinz, B., Brune, K., 2002. Cyclooxygenase-2-10 years later. J. Pharmacol. Exp. Ther. 300, 367-375.
13. Kim, Y.M., Lee, E.J., Park, S.Y., Cho, K.H., Kim, J.Y., Pyo, H., 2009. Cyclooxygenase-2 up-regulates ataxia telangiectasia and Rad3 related through extracellular signal-regulated kinase activation. Mol. Cancer Res. 7, 1158-1168.
14. Klegeris, A., McGeer, P.L., 2002. Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol. Aging 23, 787-794. (Pubitemid 35217703)
15. Klegeris, A., Walker, D.G., McGeer, P.L., 1999. Toxicity of human THP-1 monocytic cells toward neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs) Neuropharmacology 38, 1017-1025. (Pubitemid 29240618)
16. Kuo, Y.M., Emmerling, M.R., Lampert, H.C., Hempelman, S.R., Kokjohn, T.A., Woods, A.S., Cotter, R.J., Roher, A.E., 1999. High levels of circulating Aβ42 are subsequestered by plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 257, 787-791.
17. Lacky, K., Cory, M., Davis, R., Frye, S.V., Harris, P.A., Hunter, R.N., Jung, D.K., McDonald, O.B., McNutt, R.W., Peel, M.R., et al., 2000. The discovery of potent cRaf1 kinase inhibitors. Bioorg. Med. Chem. Lett. 10, 223-226.
18. Lorenzo, A., Yankner, B.A., 1994. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl Acad. Sci. USA 91, 12243-12247.
19. Mackic, B., Weiss, M.H., Miao, W., Kirkman, E., Ghiso, J., Calero, M., Bading, J., Frangione, B., Zlokovic, B.V., 1998. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid β peptide in aged squirrel monkey with cerebral amyloid angiopathy. J. Neurochem. 70, 210-215. (Pubitemid 28020845)
20. McGeer, P.L., Itagaki, S., Boyes, B.E., McGeer, E.G., 1988. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291.
21. McGeer, E.G., Schulzer, M., McGeer, E.G., 1996. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 147, 425-432. (Pubitemid 26324038)
22. Saha, K., Lajis, N.H., Israf, D.A., Hamzah, A.S., Khozirah, S., Khamis, S., Syahida, A., 2004. Evaluation of antioxidant and nitric oxide inhibitory activities of selected Malaysian medicinal plants. J. Ethnopharmacol. 92, 263-267. (Pubitemid 38610108)
23. 125I-labeled β-amyloid peptide Aβ 1-40 through the blood-brain barrier and binding to Alzheimer's disease amyloid of the Aβ1-40/vector complex. Proc. Natl Acad. Sci. USA 92, 10227-10231.
24. Samanta, M.K., Wilson, B., Santhi, K., Kumar, K.P., Suresh, B., 2006. Alzheimer's disease and its management: a review. Am. J. Ther. 13, 516-526.
25. Selkoe, D.J., 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
26. Selkoe, D.J., 2004a. Alzheimer's disease:mechanistic understanding predicts novel therapies. Ann. Intern. Med. 140, 627-638.
27. Selkoe, D.J., 2004b. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's disease. Nat. Cell Biol. 6, 1054-1061.
28. Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, C., 1992. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature 359, 325-327.
29. Tuppo, E.E., Arias, H.R., 2005. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol. 37, 289-305.
30. Uchihara, T., Akiyama, H., Kondo, H., Ikeda, K., 1997. Activated microglial cells are colocalized with perivascular deposits of amyloid-β protein in Alzheimer's disease brain. Stroke 28, 1948-1950. (Pubitemid 27459001)
31. Veld, B.A., Ruitenberg, A., Hofman, A., Launer, L.J., van Duijn, C.M., Stijnen, T., Breteler, M.M.B., Stricker, B.H.C., 2001. Non-steroidal anti-inflammatory drug use and risk of Alzheimer's disease. N. Engl. J. Med. 345, 1515-1521.
32. Wang, Z., Zhang, Q., Li, Y., Li, P., Zhang, G., Li, Y., 2009. Involvement of mitogen-activated protein kinases and nuclear factor kappa B pathways in signaling COX-2 expression in chronic rhinosinusitis. Inflamm. Res. 58, 649-658.
33. Wei, W., Wang, X., Kusiak, J.W., 2002. Signaling events in amyloid β-peptide-induced neuronal death and insulin-like growth factor I protection. J. Biol. Chem. 277, 17649-17656.
34. Wisniewski, T., Ghiso, J., Frangione, B., 1997. Biology of Aβ amyloid in Alzheimer's disease. Neurobiol. Dis. 4, 313-328.
35. Zandi, P.P., Anthony, J.C., Hayden, K.M., Mehta, K., Mayer, L., Breitner, J.C., 2002. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache Country Study. Neurology 59, 880-886.